Metformina + Vildagliptina Alter

Active Ingredient:: Metformin Hydrochloride, Vildagliptin
Origin:: EU

Metformina + Vildagliptina Alter (Metformin Hydrochloride, Vildagliptin)

Q: What is Metformina + Vildagliptina Alter used for?

Metformina + Vildagliptina Alter is a fixed‑dose oral combination of metformin and vildagliptin indicated for improving glycaemic control in adults with type 2 diabetes mellitus, usually as an adjunct to diet and exercise.

Q: How does Metformin Hydrochloride work in this product?

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, helping lower fasting blood glucose levels and improve overall glucose utilization.

Q: What is the usual dose of Metformina + Vildagliptina Alter?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy.

Q: Is Metformina + Vildagliptina Alter safe during pregnancy or breastfeeding?

Safety data are limited; the product should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and this decision must be made by the treating physician.

Q: How do I order Metformina + Vildagliptina Alter from GNH India?

Enquiries are submitted via the product page on gnhindia.com where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does this combination compare with other antidiabetic therapies?

Compared with metformin alone, the addition of vildagliptin provides complementary glucose‑dependent insulin secretion, often achieving better HbA1c reduction without the weight gain associated with some insulin secretagogues. It offers an alternative to sulfonylureas or basal insulin in many treatment algorithms.

Q: What are the storage requirements for Metformina + Vildagliptina Alter?

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container, protected from moisture, direct sunlight and excessive heat.

Q: How is Metformina + Vildagliptina Alter administered?

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with this product?

The most serious risks include lactic acidosis (particularly in patients with renal or hepatic impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, and rare cases of pancreatitis or severe skin reactions. Prompt medical attention is required if any of these occur.

Q: Who should not use Metformina + Vildagliptina Alter?

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, acute or chronic metabolic acidosis, and those currently receiving other DPP‑4 inhibitors should avoid this medication.

Metformin Hydrochloride and Vildagliptin, the active ingredients in Metformina + Vildagliptina Alter, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They are employed to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH India supplies Metformina + Vildagliptina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Alter, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformina + Vildagliptina Alter is used in the management of type 2 diabetes and related hyperglycaemic conditions.

Type 2 diabetes mellitus: improves blood glucose control when combined with diet and exercise.
Hyperglycaemia in adults: reduces fasting and post‑prandial glucose levels.
Metabolic syndrome (as part of combination therapy): assists in achieving target HbA1c.

How It Works

Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Vildagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins promote glucose‑dependent insulin secretion and suppress glucagon release, together providing better glycaemic regulation.

Side Effects

Metformina + Vildagliptina Alter may cause a range of adverse reactions.

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhoea: frequent loose stools, especially at treatment initiation.
Abdominal discomfort: cramping or bloating.
Metallic taste: transient alteration in taste perception.
Headache: mild to moderate intensity.
Upper respiratory tract infection: occasional cold‑like symptoms.

Serious or Rare Side Effects

Lactic acidosis: rare but potentially fatal metabolic disturbance.
Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
Pancreatitis: acute inflammation of the pancreas.
Severe skin reactions: such as Stevens‑Johnson syndrome.
Hepatic failure: marked liver enzyme elevation.
Renal impairment: worsening kidney function.

Precautions & Warnings

When prescribing Metformina + Vildagliptina Alter, clinicians should consider several safety aspects.

Renal function: assess eGFR before initiation and monitor periodically.
Hepatic impairment: use with caution and observe liver enzyme trends.
Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia or severe infection.
Pregnancy and lactation: evaluate risk‑benefit; limited data are available.
Drug interactions: review concomitant medicines for potential interactions.
Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Metformina + Vildagliptina Alter can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to risk of lactic acidosis.
Iodinated contrast agents: discontinue metformin before and after imaging to prevent accumulation.
Co‑administration with other DPP‑4 inhibitors: duplication of effect should be avoided.
Strong CYP2C9 inhibitors: may increase Vildagliptin plasma levels.

Moderate Interactions (Monitor Closely)

Sulfonylureas: heightened risk of hypoglycaemia; adjust dose as needed.
Beta‑blockers: may mask hypoglycaemia symptoms, requiring vigilant glucose monitoring.
Diuretics: can affect renal function, necessitating periodic assessment of kidney parameters.

Frequently Asked Questions

Metformina + Vildagliptina Alter is a fixed‑dose oral combination of metformin and vildagliptin indicated for improving glycaemic control in adults with type 2 diabetes mellitus, usually as an adjunct to diet and exercise.

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, helping lower fasting blood glucose levels and improve overall glucose utilization.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy.

Safety data are limited; the product should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and this decision must be made by the treating physician.

Enquiries are submitted via the product page on gnhindia.com where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of vildagliptin provides complementary glucose‑dependent insulin secretion, often achieving better HbA1c reduction without the weight gain associated with some insulin secretagogues. It offers an alternative to sulfonylureas or basal insulin in many treatment algorithms.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container, protected from moisture, direct sunlight and excessive heat.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis (particularly in patients with renal or hepatic impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, and rare cases of pancreatitis or severe skin reactions. Prompt medical attention is required if any of these occur.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, acute or chronic metabolic acidosis, and those currently receiving other DPP‑4 inhibitors should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.